Cargando…

Chemotherapy for biliary tract cancer: real-world experience in a single institute

The standard chemotherapy regimen for unresectable or recurrent biliary tract cancer is gemcitabine combined with cisplatin (GC). To evaluate the effectiveness and safety of chemotherapy in patients with unresectable or recurrent biliary tract cancer in the real world, we retrospectively analyzed th...

Descripción completa

Detalles Bibliográficos
Autores principales: Maeda, Osamu, Ebata, Tomoki, Shimokata, Tomoya, Matsuoka, Ayumu, Inada-Inoue, Megumi, Morita, Sachi, Takano, Yuko, Urakawa, Hiroshi, Miyai, Yuki, Sugishita, Mihoko, Mitsuma, Ayako, Ando, Masahiko, Mizuno, Takashi, Nagino, Masato, Ando, Yuichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nagoya University 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719462/
https://www.ncbi.nlm.nih.gov/pubmed/33311803
http://dx.doi.org/10.18999/nagjms.82.4.725
_version_ 1783619684960043008
author Maeda, Osamu
Ebata, Tomoki
Shimokata, Tomoya
Matsuoka, Ayumu
Inada-Inoue, Megumi
Morita, Sachi
Takano, Yuko
Urakawa, Hiroshi
Miyai, Yuki
Sugishita, Mihoko
Mitsuma, Ayako
Ando, Masahiko
Mizuno, Takashi
Nagino, Masato
Ando, Yuichi
author_facet Maeda, Osamu
Ebata, Tomoki
Shimokata, Tomoya
Matsuoka, Ayumu
Inada-Inoue, Megumi
Morita, Sachi
Takano, Yuko
Urakawa, Hiroshi
Miyai, Yuki
Sugishita, Mihoko
Mitsuma, Ayako
Ando, Masahiko
Mizuno, Takashi
Nagino, Masato
Ando, Yuichi
author_sort Maeda, Osamu
collection PubMed
description The standard chemotherapy regimen for unresectable or recurrent biliary tract cancer is gemcitabine combined with cisplatin (GC). To evaluate the effectiveness and safety of chemotherapy in patients with unresectable or recurrent biliary tract cancer in the real world, we retrospectively analyzed the clinical courses of patients who underwent chemotherapy with GC from January 2015 to November 2019. Forty-eight patients underwent the GC regimen. One patient (2.1%) achieved a complete response, seven patients (14.6%) achieved a partial response, 26 patients (54.2) achieved stable disease, 11 patients (22.9%) achieved progressive disease, and 3 patients (6.3%) were not evaluable. The overall response rate was 16.7%. The median overall survival was 14.2 months (95% CI: 13.8–14.6), and the median progression-free survival was 7.7 months (95% CI: 4.2–11.2). Thirty-nine patients (81.3%) experienced grade 3 or higher severe adverse events as follows: 54.2% experienced neutropenia, 20.8% experienced anemia, 12.5% experienced thrombocytopenia and 20.8% experienced biliary tract infection. As a second-line chemotherapy, S-1 was used in seventeen patients, and stable disease was achieved in three patients (17.6%). The GC regimen for biliary tract cancer is effective and safe for unresectable or recurrent biliary tract cancer in routine clinical practice.
format Online
Article
Text
id pubmed-7719462
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nagoya University
record_format MEDLINE/PubMed
spelling pubmed-77194622020-12-11 Chemotherapy for biliary tract cancer: real-world experience in a single institute Maeda, Osamu Ebata, Tomoki Shimokata, Tomoya Matsuoka, Ayumu Inada-Inoue, Megumi Morita, Sachi Takano, Yuko Urakawa, Hiroshi Miyai, Yuki Sugishita, Mihoko Mitsuma, Ayako Ando, Masahiko Mizuno, Takashi Nagino, Masato Ando, Yuichi Nagoya J Med Sci Original Paper The standard chemotherapy regimen for unresectable or recurrent biliary tract cancer is gemcitabine combined with cisplatin (GC). To evaluate the effectiveness and safety of chemotherapy in patients with unresectable or recurrent biliary tract cancer in the real world, we retrospectively analyzed the clinical courses of patients who underwent chemotherapy with GC from January 2015 to November 2019. Forty-eight patients underwent the GC regimen. One patient (2.1%) achieved a complete response, seven patients (14.6%) achieved a partial response, 26 patients (54.2) achieved stable disease, 11 patients (22.9%) achieved progressive disease, and 3 patients (6.3%) were not evaluable. The overall response rate was 16.7%. The median overall survival was 14.2 months (95% CI: 13.8–14.6), and the median progression-free survival was 7.7 months (95% CI: 4.2–11.2). Thirty-nine patients (81.3%) experienced grade 3 or higher severe adverse events as follows: 54.2% experienced neutropenia, 20.8% experienced anemia, 12.5% experienced thrombocytopenia and 20.8% experienced biliary tract infection. As a second-line chemotherapy, S-1 was used in seventeen patients, and stable disease was achieved in three patients (17.6%). The GC regimen for biliary tract cancer is effective and safe for unresectable or recurrent biliary tract cancer in routine clinical practice. Nagoya University 2020-11 /pmc/articles/PMC7719462/ /pubmed/33311803 http://dx.doi.org/10.18999/nagjms.82.4.725 Text en http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Paper
Maeda, Osamu
Ebata, Tomoki
Shimokata, Tomoya
Matsuoka, Ayumu
Inada-Inoue, Megumi
Morita, Sachi
Takano, Yuko
Urakawa, Hiroshi
Miyai, Yuki
Sugishita, Mihoko
Mitsuma, Ayako
Ando, Masahiko
Mizuno, Takashi
Nagino, Masato
Ando, Yuichi
Chemotherapy for biliary tract cancer: real-world experience in a single institute
title Chemotherapy for biliary tract cancer: real-world experience in a single institute
title_full Chemotherapy for biliary tract cancer: real-world experience in a single institute
title_fullStr Chemotherapy for biliary tract cancer: real-world experience in a single institute
title_full_unstemmed Chemotherapy for biliary tract cancer: real-world experience in a single institute
title_short Chemotherapy for biliary tract cancer: real-world experience in a single institute
title_sort chemotherapy for biliary tract cancer: real-world experience in a single institute
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719462/
https://www.ncbi.nlm.nih.gov/pubmed/33311803
http://dx.doi.org/10.18999/nagjms.82.4.725
work_keys_str_mv AT maedaosamu chemotherapyforbiliarytractcancerrealworldexperienceinasingleinstitute
AT ebatatomoki chemotherapyforbiliarytractcancerrealworldexperienceinasingleinstitute
AT shimokatatomoya chemotherapyforbiliarytractcancerrealworldexperienceinasingleinstitute
AT matsuokaayumu chemotherapyforbiliarytractcancerrealworldexperienceinasingleinstitute
AT inadainouemegumi chemotherapyforbiliarytractcancerrealworldexperienceinasingleinstitute
AT moritasachi chemotherapyforbiliarytractcancerrealworldexperienceinasingleinstitute
AT takanoyuko chemotherapyforbiliarytractcancerrealworldexperienceinasingleinstitute
AT urakawahiroshi chemotherapyforbiliarytractcancerrealworldexperienceinasingleinstitute
AT miyaiyuki chemotherapyforbiliarytractcancerrealworldexperienceinasingleinstitute
AT sugishitamihoko chemotherapyforbiliarytractcancerrealworldexperienceinasingleinstitute
AT mitsumaayako chemotherapyforbiliarytractcancerrealworldexperienceinasingleinstitute
AT andomasahiko chemotherapyforbiliarytractcancerrealworldexperienceinasingleinstitute
AT mizunotakashi chemotherapyforbiliarytractcancerrealworldexperienceinasingleinstitute
AT naginomasato chemotherapyforbiliarytractcancerrealworldexperienceinasingleinstitute
AT andoyuichi chemotherapyforbiliarytractcancerrealworldexperienceinasingleinstitute